Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Coeptis Therapeutics Hldgs Inc (COEP)

Coeptis Therapeutics Hldgs Inc (COEP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,083
  • Shares Outstanding, K 36,090
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,270 K
  • 60-Month Beta -0.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.55
Trade COEP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.90
  • Most Recent Earnings $-0.08 on 03/25/24
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +256,253.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2943 +13.80%
on 04/01/24
0.4800 -30.23%
on 04/11/24
+0.0375 (+12.61%)
since 03/28/24
3-Month
0.2851 +17.47%
on 03/28/24
0.6790 -50.68%
on 02/29/24
-0.2451 (-42.26%)
since 01/29/24
52-Week
0.2851 +17.47%
on 03/28/24
2.1899 -84.71%
on 05/23/23
-0.8551 (-71.86%)
since 04/28/23

Most Recent Stories

More News
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)
Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.3349 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Coeptis Therapeutics Holdings Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer. Coeptis Therapeutics Holdings Inc., formerly known as Bull Horn Holdings Corp.,...

See More

Key Turning Points

3rd Resistance Point 0.3586
2nd Resistance Point 0.3483
1st Resistance Point 0.3416
Last Price 0.3349
1st Support Level 0.3246
2nd Support Level 0.3143
3rd Support Level 0.3076

See More

52-Week High 2.1899
Fibonacci 61.8% 1.4623
Fibonacci 50% 1.2375
Fibonacci 38.2% 1.0127
Last Price 0.3349
52-Week Low 0.2851

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar